Detalles de la búsqueda
1.
Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.
Health Qual Life Outcomes
; 17(1): 61, 2019 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975150
2.
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Br J Haematol
; 172(1): 97-110, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26537529
3.
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Blood
; 123(9): 1309-18, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24345751
4.
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Am J Hematol
; 90(9): 755-68, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26040495
5.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 346-7, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674873
6.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 348-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674874
7.
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Am J Hematol
; 89(7): 732-42, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24711212
8.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
J Clin Oncol
; 32(2): 68-75, 2014 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24323026
9.
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Clin Cancer Res
; 18(4): 1092-100, 2012 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22179664
10.
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
J Clin Oncol
; 28(8): 1301-7, 2010 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20142587
Resultados
1 -
10
de 10
1
Próxima >
>>